MaxCyte, Inc.(MXCT)Earnings, Financials & Key Ratios
MXCT•NASDAQ
$0.87
$93M mkt cap·Price updated May 7, 2026
AboutMaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.Show more
- Revenue$33M-14.5%
- EBITDA-$41M+10.7%
- Net Income-$45M-8.7%
- EPS (Diluted)-0.42-7.7%
- Gross Margin81.16%-0.6%
- EBITDA Margin-125.5%-4.5%
- Operating Margin-138.3%-4.3%
- Net Margin-135.14%-27.1%
- ROE-23.63%-26.2%
- ROIC-18.73%+2.2%
- Debt/Equity0.10+19.7%
MXCT Key Insights
MaxCyte, Inc. (MXCT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MXCT Price & Volume
MaxCyte, Inc. (MXCT) stock price & volume — 10-year historical chart
Loading chart...
MXCT Growth Metrics
MaxCyte, Inc. (MXCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.52%
5 Years4.76%
3 Years-9.3%
TTM-14.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-12.5%
Return on Capital
10 Years-32.58%
5 Years-16.84%
3 Years-20.76%
Last Year-22.18%
MXCT Peer Comparison
MaxCyte, Inc. (MXCT) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BTBT | 589.49M | 1.83 | 9.15 | 264.59% | 21.41% | 0.03 | ||
 LNTH | 5.92B | 91.00 | 26.69 | 0.5% | 18.05% | 24.33% | 0.00 | |
 NVAX | 1.5B | 9.23 | 3.63 | 64.69% | -14.73% | |||
 PSNL | 531.94M | 5.99 | -6.58 | -100% | -194.83% | -43.52% | 0.12 | |
 BCYC | 338.69M | 4.89 | -1.55 | 105.77% | -344.95% | -35.74% | 0.03 | |
 XNCR | 902.8M | 12.31 | -9.93 | 13.65% | -185.71% | -23.68% | 0.30 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 |
Compare MXCT vs Peers
MaxCyte, Inc. (MXCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MXCT Income Statement
MaxCyte, Inc. (MXCT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 13.98M | 16.67M | 21.62M | 26.17M | 33.89M | 44.26M | 41.29M | 38.63M | 33.03M |
| Revenue Growth % | 13.98% | 19.18% | 29.72% | 21.04% | 29.52% | 30.59% | -6.72% | -6.44% | -14.5% |
| Cost of Goods Sold | 1.45M | 1.84M | 2.5M | 2.77M | 3.65M | 5.1M | 4.74M | 7.1M | 6.22M |
| COGS % of Revenue | 10.39% | 11.04% | 11.56% | 10.57% | 10.76% | 11.52% | 11.49% | 18.38% | 18.84% |
| Gross Profit | 12.53M▲ 0% | 14.83M▲ 18.3% | 19.12M▲ 29.0% | 23.4M▲ 22.4% | 30.25M▲ 29.2% | 39.16M▲ 29.5% | 36.55M▼ 6.7% | 31.53M▼ 13.7% | 26.8M▼ 15.0% |
| Gross Margin % | 89.61% | 88.96% | 88.44% | 89.43% | 89.24% | 88.48% | 88.51% | 81.62% | 81.16% |
| Gross Profit Growth % | 14.32% | 18.31% | 28.96% | 22.39% | 29.25% | 29.48% | -6.68% | -13.73% | -14.98% |
| Operating Expenses | 21.82M | 23.25M | 31.54M | 34.46M | 48.44M | 66.52M | 84.84M | 82.72M | 72.48M |
| OpEx % of Revenue | 156.05% | 139.51% | 145.89% | 131.68% | 142.9% | 150.3% | 205.5% | 214.16% | 219.46% |
| Selling, General & Admin | 10.54M | 12.01M | 13.41M | 15.7M | 31.68M | 44.48M | 57.04M | 56.35M | 47.04M |
| SG&A % of Revenue | 75.36% | 72.05% | 62.01% | 59.99% | 93.46% | 100.5% | 138.16% | 145.89% | 142.43% |
| Research & Development | 11.28M | 11.24M | 17.59M | 17.73M | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M |
| R&D % of Revenue | 80.69% | 67.46% | 81.37% | 67.77% | 45.46% | 44.09% | 57.68% | 57.54% | 63.05% |
| Other Operating Expenses | 0 | 0 | 541.3K | 1.03M | 1.35M | 2.53M | 3.98M | 4.14M | 4.62M |
| Operating Income | -9.29M▲ 0% | -8.42M▲ 9.3% | -12.42M▼ 47.4% | -11.06M▲ 11.0% | -18.19M▼ 64.5% | -27.36M▼ 50.4% | -48.3M▼ 76.5% | -51.2M▼ 6.0% | -45.67M▲ 10.8% |
| Operating Margin % | -66.44% | -50.55% | -57.44% | -42.25% | -53.66% | -61.82% | -116.98% | -132.54% | -138.3% |
| Operating Income Growth % | -241.18% | 9.33% | -47.42% | 10.98% | -64.5% | -50.43% | -76.53% | -6% | 10.79% |
| EBITDA | -9.15M | -8.08M | -11.81M | -10.01M | -16.76M | -24.66M | -44.13M | -46.41M | -41.45M |
| EBITDA Margin % | -65.42% | -48.48% | -54.61% | -38.25% | -49.46% | -55.72% | -106.88% | -120.14% | -125.5% |
| EBITDA Growth % | -249.5% | 11.67% | -46.1% | 15.22% | -67.5% | -47.11% | -78.92% | -5.16% | 10.68% |
| D&A (Non-Cash Add-back) | 142.9K | 344K | 613.5K | 1.05M | 1.42M | 2.7M | 4.17M | 4.79M | 4.23M |
| EBIT | -9.29M | -8.25M | -12.21M | -10.99M | -18.04M | -27.36M | -48.3M | -51.2M | 0 |
| Net Interest Income | -625.3K | -444.3K | -475K | -759.7K | -893.6K | 3.79M | 10.38M | 10.14M | 0 |
| Interest Income | 0 | 170.3K | 206.1K | 65.9K | 150.8K | 3.92M | 10.38M | 10.14M | 7.27M |
| Interest Expense | 625.3K | 614.6K | 681.1K | 825.6K | 1.04M | 126.9K | 0 | 0 | 0 |
| Other Income/Expense | -625.3K | -444.3K | -475K | -759.7K | -893.6K | 3.79M | 10.38M | 10.14M | 1.04M |
| Pretax Income | -9.92M▲ 0% | -8.87M▲ 10.6% | -12.89M▼ 45.4% | -11.82M▲ 8.4% | -19.08M▼ 61.5% | -23.57M▼ 23.5% | -37.92M▼ 60.9% | -41.05M▼ 8.3% | -44.63M▼ 8.7% |
| Pretax Margin % | -70.91% | -53.21% | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -106.29% | -135.14% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -9.92M▲ 0% | -8.87M▲ 10.6% | -12.89M▼ 45.4% | -11.82M▲ 8.4% | -19.08M▼ 61.5% | -23.57M▼ 23.5% | -37.92M▼ 60.9% | -41.05M▼ 8.3% | -44.63M▼ 8.7% |
| Net Margin % | -70.91% | -53.21% | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -106.29% | -135.14% |
| Net Income Growth % | -196.43% | 10.57% | -45.39% | 8.36% | -61.49% | -23.52% | -60.89% | -8.26% | -8.71% |
| Net Income (Continuing) | -9.92M | -8.87M | -12.89M | -11.82M | -19.08M | -23.57M | -37.92M | -41.05M | -44.63M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.20▲ 0% | -0.17▲ 15.0% | -0.24▼ 41.2% | -0.18▲ 25.0% | -0.22▼ 22.2% | -0.19▲ 13.6% | -0.37▼ 94.7% | -0.39▼ 5.4% | -0.42▼ 7.7% |
| EPS Growth % | -100.4% | 15% | -41.18% | 25% | -22.22% | 13.64% | -94.74% | -5.41% | -7.69% |
| EPS (Basic) | -0.20 | -0.17 | -0.24 | -0.18 | -0.22 | -0.19 | -0.37 | -0.39 | -0.42 |
| Diluted Shares Outstanding | 48.64M | 51.18M | 56.4M | 69.46M | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
| Basic Shares Outstanding | 48.64M | 51.18M | 56.4M | 69.46M | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MXCT Balance Sheet
MaxCyte, Inc. (MXCT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 30.55M | 22.45M | 24.45M | 45.25M | 270.43M | 252.27M | 190.19M | 171.68M | 118.37M |
| Cash & Short-Term Investments | 25.34M | 14.44M | 16.71M | 34.76M | 255.04M | 227.34M | 168.29M | 154.48M | 20.07M |
| Cash Only | 25.34M | 11.25M | 15.21M | 18.76M | 47.78M | 11.06M | 46.51M | 27.88M | 20.07M |
| Short-Term Investments | 0 | 3.19M | 1.5M | 16.01M | 207.26M | 216.28M | 121.78M | 126.6M | 0 |
| Accounts Receivable | 3.2M | 4.9M | 3.24M | 5.17M | 6.88M | 11.18M | 5.78M | 4.68M | 3.5M |
| Days Sales Outstanding | 83.4 | 107.41 | 54.77 | 72.14 | 74.06 | 92.16 | 51.08 | 44.24 | 38.71 |
| Inventory | 1.35M | 2.24M | 3.7M | 4.32M | 5.2M | 8.58M | 12.23M | 8.91M | 7.55M |
| Days Inventory Outstanding | 338.35 | 444.9 | 540.64 | 569.3 | 520.83 | 614.37 | 941.29 | 458.25 | 442.73 |
| Other Current Assets | 665.8K | 863.7K | 797.1K | 0 | 0 | 1.91M | 3.9M | 3.61M | 87.25M |
| Total Non-Current Assets | 847.6K | 1.82M | 5.53M | 6.53M | 13.69M | 34.39M | 78.08M | 67.79M | 84.14M |
| Property, Plant & Equipment | 847.6K | 1.82M | 5.53M | 6.49M | 13.37M | 33.58M | 34.75M | 30.47M | 28.45M |
| Fixed Asset Turnover | 16.50x | 9.17x | 3.91x | 4.03x | 2.53x | 1.32x | 1.19x | 1.27x | 1.16x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 650K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 42.94M | 35.78M | 52.57M |
| Other Non-Current Assets | 0 | 0 | 0 | 33.9K | 316.7K | 809K | 388K | 1.53M | 2.47M |
| Total Assets | 31.4M▲ 0% | 24.27M▼ 22.7% | 29.99M▲ 23.6% | 51.78M▲ 72.7% | 284.12M▲ 448.7% | 286.65M▲ 0.9% | 268.27M▼ 6.4% | 239.47M▼ 10.7% | 202.51M▼ 15.4% |
| Asset Turnover | 0.45x | 0.69x | 0.72x | 0.51x | 0.12x | 0.15x | 0.15x | 0.16x | 0.16x |
| Asset Growth % | 95.35% | -22.71% | 23.56% | 72.68% | 448.7% | 0.89% | -6.41% | -10.74% | -15.44% |
| Total Current Liabilities | 7.24M | 6.57M | 9.34M | 11.61M | 15.62M | 15.43M | 17.86M | 15.78M | 14.27M |
| Accounts Payable | 4.33M | 1.03M | 2.09M | 890.2K | 1.82M | 292K | 743K | 1.36M | 1.4M |
| Days Payables Outstanding | 1.09K | 204.74 | 305.15 | 117.43 | 182.16 | 20.91 | 57.19 | 69.81 | 82.19 |
| Short-Term Debt | 850.9K | 0 | 0 | 0 | 0 | 0 | 0 | 864K | 1.46M |
| Deferred Revenue (Current) | 2.06M | 2.45M | 3.19M | 4.84M | 6.75M | 0 | 5.07M | 5.25M | 3.6M |
| Other Current Liabilities | -850.9K | 0 | 0 | 0 | 0 | 6.71M | 0 | 8.3M | 9.21M |
| Current Ratio | 4.22x | 3.42x | 2.62x | 3.90x | 17.32x | 16.35x | 10.65x | 10.88x | 8.30x |
| Quick Ratio | 4.03x | 3.07x | 2.22x | 3.52x | 16.98x | 15.80x | 9.97x | 10.32x | 7.77x |
| Cash Conversion Cycle | -666.14 | 347.57 | 290.26 | 524.01 | 412.73 | 685.62 | 935.18 | 432.68 | 399.26 |
| Total Non-Current Liabilities | 4.56M | 5.41M | 7.04M | 6.94M | 5.61M | 17.26M | 18.25M | 17.44M | 16.75M |
| Long-Term Debt | 4.18M | 5.06M | 4.9M | 4.92M | 0 | 0 | 0 | 0 | 16.49M |
| Capital Lease Obligations | 0 | 0 | 1.81M | 1.38M | 5.15M | 15.94M | 17.97M | 17.17M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 384.5K | 357.3K | 338.1K | 646.6K | 450.2K | 1.32M | 283K | 274K | 263K |
| Total Liabilities | 11.8M | 11.99M | 16.38M | 18.55M | 21.22M | 32.69M | 36.11M | 33.22M | 31.02M |
| Total Debt | 5.03M | 5.06M | 7.21M | 6.97M | 5.68M | 16.09M | 18.74M | 18.03M | 17.94M |
| Net Debt | -20.31M | -6.19M | -8M | -11.79M | -42.1M | 5.03M | -27.76M | -9.85M | -2.12M |
| Debt / Equity | 0.26x | 0.41x | 0.53x | 0.21x | 0.02x | 0.06x | 0.08x | 0.09x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -14.86x | -13.71x | -18.24x | -13.39x | -17.42x | -215.61x | - | - | - |
| Total Equity | 19.6M▲ 0% | 12.28M▼ 37.3% | 13.6M▲ 10.7% | 33.23M▲ 144.3% | 262.9M▲ 691.3% | 253.97M▼ 3.4% | 232.17M▼ 8.6% | 206.25M▼ 11.2% | 171.49M▼ 16.9% |
| Equity Growth % | 285.5% | -37.33% | 10.75% | 144.27% | 691.25% | -3.4% | -8.58% | -11.16% | -16.85% |
| Book Value per Share | 0.40 | 0.24 | 0.24 | 0.48 | 2.90 | 2.50 | 2.25 | 1.97 | 1.61 |
| Total Shareholders' Equity | 19.6M | 12.28M | 13.6M | 33.23M | 262.9M | 253.97M | 232.17M | 206.25M | 171.49M |
| Common Stock | 509K | 513.3K | 574K | 773.8K | 1.01M | 1.02M | 1.04M | 1.06M | 1.07M |
| Retained Earnings | -61.64M | -70.51M | -83.41M | -95.22M | -114.3M | -137.88M | -175.8M | -216.85M | -261.48M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MXCT Cash Flow Statement
MaxCyte, Inc. (MXCT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.68M | -10.49M | -8.8M | -8.78M | -10.68M | -14.78M | -21.69M | -27.61M | -34.41M |
| Operating CF Margin % | -69.2% | -62.92% | -40.71% | -33.56% | -31.51% | -33.4% | -52.52% | -71.48% | -104.19% |
| Operating CF Growth % | -314.44% | -8.37% | 16.07% | 0.23% | -21.61% | -38.42% | -46.7% | -27.32% | -24.63% |
| Net Income | -9.92M | -8.87M | -12.89M | -11.82M | -19.08M | -23.57M | -37.92M | -41.05M | -44.63M |
| Depreciation & Amortization | 142.9K | 344K | 613.5K | 1.05M | 1.42M | 2.7M | 4.57M | 4.32M | 5.14M |
| Stock-Based Compensation | 514.5K | 1.32M | 1.75M | 2.47M | 7.96M | 0 | 13.98M | 0 | 9.21M |
| Deferred Taxes | 0 | 96.4K | 37.3K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 101.3K | 74.7K | 76.9K | 373K | 664.6K | 9.3M | -6.13M | 9.88M | -4.13M |
| Working Capital Changes | -518.8K | -3.46M | 1.61M | -858.2K | -1.64M | -3.21M | 3.82M | -751K | 0 |
| Change in Receivables | -784.9K | -1.95M | 1.59M | -1.81M | -1.71M | -6.69M | 7.14M | 1.23M | 1.15M |
| Change in Inventory | -174.9K | -1.29M | -1.89M | -890.6K | -1.41M | -3.49M | -4.53M | 1.36M | 676K |
| Change in Payables | 849K | -689.1K | 1.05M | 391K | 2.09M | -149.7K | 3.25M | -1.88M | -3.72M |
| Cash from Investing | -609.7K | -3.83M | 454.5K | -16.58M | -195.01M | -24.82M | 54.98M | 6.93M | 25.93M |
| Capital Expenditures | -609.7K | -709.7K | -1.27M | -2.07M | -3.83M | -18.48M | -3.7M | -1.65M | -1.77M |
| CapEx % of Revenue | 4.36% | 4.26% | 5.88% | 7.92% | 11.31% | 41.75% | 8.96% | 4.27% | 5.35% |
| Acquisitions | 0 | 0 | -1.73M | 0 | 0 | 0 | 0 | 0 | -1.77M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -3.12M | 1.73M | 0 | 4.6K | 0 | 9K | 0 | 0 |
| Cash from Financing | 23.9M | 226.8K | 12.31M | 28.9M | 234.72M | 2.89M | 2.14M | 2.06M | 656K |
| Debt Issued (Net) | -14.3K | -3.2K | -152.2K | -63.7K | -4.99M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 23.9M | 0 | 12.33M | 28.57M | 236.08M | 2.89M | 269K | 2.06M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 224K |
| Other Financing | 16.2K | 230K | 132.7K | 401K | 3.63M | 0 | 1.87M | 0 | 656K |
| Net Change in Cash | 13.61M▲ 0% | -14.09M▼ 203.5% | 3.96M▲ 128.1% | 3.54M▼ 10.6% | 29.03M▲ 719.0% | -36.72M▼ 226.5% | 35.44M▲ 196.5% | -18.62M▼ 152.5% | -7.82M▲ 58.0% |
| Free Cash Flow | -10.29M▲ 0% | -11.2M▼ 8.8% | -10.07M▲ 10.0% | -10.85M▼ 7.7% | -14.51M▼ 33.7% | -33.26M▼ 129.2% | -25.39M▲ 23.7% | -29.26M▼ 15.3% | -36.18M▼ 23.6% |
| FCF Margin % | -73.56% | -67.18% | -46.59% | -41.48% | -42.82% | -75.15% | -61.49% | -75.75% | -109.54% |
| FCF Growth % | -302.8% | -8.85% | 10.03% | -7.75% | -33.72% | -129.16% | 23.67% | -15.26% | -23.64% |
| FCF per Share | -0.21 | -0.22 | -0.18 | -0.16 | -0.16 | -0.33 | -0.25 | -0.28 | -0.34 |
| FCF Conversion (FCF/Net Income) | 0.98x | 1.18x | 0.68x | 0.74x | 0.56x | 0.63x | 0.57x | 0.67x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 421.4K | 420.9K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MXCT Key Ratios
MaxCyte, Inc. (MXCT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -334.4% | -80.36% | -55.64% | -99.64% | -50.47% | -12.89% | -9.12% | -15.6% | -18.73% | -23.63% |
| Return on Invested Capital (ROIC) | - | - | -235.1% | -159.34% | -61.34% | -11.26% | -8.55% | -15.63% | -19.16% | -18.73% |
| Gross Margin | 89.34% | 89.61% | 88.96% | 88.44% | 89.43% | 89.24% | 88.48% | 88.51% | 81.62% | 81.16% |
| Net Margin | -27.27% | -70.91% | -53.21% | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -106.29% | -135.14% |
| Debt / Equity | 0.98x | 0.26x | 0.41x | 0.53x | 0.21x | 0.02x | 0.06x | 0.08x | 0.09x | 0.10x |
| Interest Coverage | -4.27x | -14.86x | -13.71x | -18.24x | -13.39x | -17.42x | -215.61x | - | - | - |
| FCF Conversion | 0.70x | 0.98x | 1.18x | 0.68x | 0.74x | 0.56x | 0.63x | 0.57x | 0.67x | 0.77x |
| Revenue Growth | 32.07% | 13.98% | 19.18% | 29.72% | 21.04% | 29.52% | 30.59% | -6.72% | -6.44% | -14.5% |
MXCT Frequently Asked Questions
MaxCyte, Inc. (MXCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MaxCyte, Inc. (MXCT) reported $33.0M in revenue for fiscal year 2025. This represents a 553% increase from $5.1M in 2012.
MaxCyte, Inc. (MXCT) saw revenue decline by 14.5% over the past year.
MaxCyte, Inc. (MXCT) reported a net loss of $44.6M for fiscal year 2025.
Dividend & Returns
MaxCyte, Inc. (MXCT) has a return on equity (ROE) of -23.6%. Negative ROE indicates the company is unprofitable.
MaxCyte, Inc. (MXCT) had negative free cash flow of $36.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More MXCT
MaxCyte, Inc. (MXCT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates